Assessing the accuracy and reliability of ChatGPT's medical responses about thyroid cancer.

PURPOSE: ChatGPT has the potential to offer patient-friendly support. Thyroid carcinoma has become increasingly prevalent in recent years. This study aimed to assess ChatGPT's accuracy and adequacy in answering questions about information, management, and emotional support related to thyroid cancer. METHODS: We conducted a three-step study. In the first step, ChatGPT responded to 30 questions about thyroid cancer. In the second step, we presented three different cases of thyroid cancer patients and asked ChatGPT about their diagnosis, treatment management, and follow-up. In the third step, we inquired about emotional support for patients and their families. Three expert endocrinologists graded these responses according to ATA guidelines. RESULTS: We showed that ChatGPT regurgitated extensive knowledge of thyroid cancer (76.66% correct), but only small proportions (6.66%) were labeled as mixed with correct and incorrect/outdated data. However, it was inadequate in the evaluation of clinical cases of thyroid cancer. It mentioned treatment and follow-up recommendations in a general framework, not patient-specific. Also, it provided practical and multifaceted emotional support advice to patients and caregivers regarding the next steps and adjusting to a new diagnosis. CONCLUSION: Our study is the first to evaluate the competence and reliability of ChatGPT in thyroid cancer. Although ChatGPT is moderately competent in obtaining information about thyroid cancer, it has not yet been determined to be sufficiently competent and reliable in case management. It has been found effective in guiding patients and their relatives regarding emotional support.

Comparison of soluble suppression of tumorigenicity 2 and brachial hemodynamic parameters between dialysis modalities in patients with end-stage kidney disease.

PURPOSE: Major cardiovascular events (MACE) are the leading cause of mortality in patients with chronic kidney disease. Although hemodialysis (HD) and peritoneal dialysis (PD) are comparable in survival, patients with HD have a significantly higher risk of developing MACE. Soluble suppression of tumorigenicity 2 (sST2) is a cardiac biomarker, that does not vary with age, gender, and kidney function. This study aimed to compare arterial stiffness, fluid status, and sST2 levels, between patients with PD and those with in-center HD. METHODS: This was a cross-sectional study, which was conducted with 36 PD patients, 36 HD patients, and 36 age, and gender-matched healthy controls. We used noninvasive methods for the assessment of arterial stiffness and fluid status. RESULTS: The patients with PD overhydrated compared to HD patients and healthy control (p < 0.001, and p = 0.05, respectively). Patients with PD had higher central systolic blood pressure and central pulse pressure than patients with HD and the control group (p = 0.004, and p = 0.01; p < 0.001, and p = 0.004, respectively). HD patients had a significantly higher level of plasma sST2 level compared to PD patients and the control group (p = 0.03, and p = 0.005). HD as maintenance dialysis modality and dialysis vintage was associated with higher plasma sST2 concentration, and having a residual renal function in dialysis patients was related to the lower plasma sST2 concentration. CONCLUSION: PD is associated with better sST2 levels even though higher volume load than HD. In addition, the loss of RRF may be the most important factor related to increased sST2.